AU2004274212B2 - Dimethoxy docetaxel acetone solvate et method for the preparation thereof - Google Patents

Dimethoxy docetaxel acetone solvate et method for the preparation thereof Download PDF

Info

Publication number
AU2004274212B2
AU2004274212B2 AU2004274212A AU2004274212A AU2004274212B2 AU 2004274212 B2 AU2004274212 B2 AU 2004274212B2 AU 2004274212 A AU2004274212 A AU 2004274212A AU 2004274212 A AU2004274212 A AU 2004274212A AU 2004274212 B2 AU2004274212 B2 AU 2004274212B2
Authority
AU
Australia
Prior art keywords
hydroxy
acetone
set forth
dimethoxy
oxotax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2004274212A
Other languages
English (en)
Other versions
AU2004274212A1 (en
Inventor
Eric Didier
Marc-Antoine Perrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004274212(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2004274212A1 publication Critical patent/AU2004274212A1/en
Application granted granted Critical
Publication of AU2004274212B2 publication Critical patent/AU2004274212B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
AU2004274212A 2003-09-19 2004-09-16 Dimethoxy docetaxel acetone solvate et method for the preparation thereof Active 2026-12-08 AU2004274212B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0311016 2003-09-19
FR0311016A FR2859996B1 (fr) 2003-09-19 2003-09-19 Solvat acetonique du dimethoxy docetaxel et son procede de preparation
PCT/FR2004/002344 WO2005028462A1 (fr) 2003-09-19 2004-09-16 Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Publications (2)

Publication Number Publication Date
AU2004274212A1 AU2004274212A1 (en) 2005-03-31
AU2004274212B2 true AU2004274212B2 (en) 2010-03-04

Family

ID=34224354

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004274212A Active 2026-12-08 AU2004274212B2 (en) 2003-09-19 2004-09-16 Dimethoxy docetaxel acetone solvate et method for the preparation thereof

Country Status (37)

Country Link
US (1) US7241907B2 (cg-RX-API-DMAC10.html)
EP (1) EP1667986B1 (cg-RX-API-DMAC10.html)
JP (1) JP5010279B2 (cg-RX-API-DMAC10.html)
KR (1) KR101123588B1 (cg-RX-API-DMAC10.html)
CN (1) CN100429207C (cg-RX-API-DMAC10.html)
AR (1) AR045667A1 (cg-RX-API-DMAC10.html)
AU (1) AU2004274212B2 (cg-RX-API-DMAC10.html)
BE (1) BE2013C036I2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0414492A8 (cg-RX-API-DMAC10.html)
CA (1) CA2539309A1 (cg-RX-API-DMAC10.html)
CR (1) CR8292A (cg-RX-API-DMAC10.html)
CY (2) CY1114575T1 (cg-RX-API-DMAC10.html)
DK (1) DK1667986T3 (cg-RX-API-DMAC10.html)
ES (1) ES2403149T4 (cg-RX-API-DMAC10.html)
FR (2) FR2859996B1 (cg-RX-API-DMAC10.html)
HR (1) HRP20130322T1 (cg-RX-API-DMAC10.html)
HU (1) HUS1300025I1 (cg-RX-API-DMAC10.html)
IL (1) IL174240A (cg-RX-API-DMAC10.html)
LU (1) LU92172I2 (cg-RX-API-DMAC10.html)
MA (1) MA28045A1 (cg-RX-API-DMAC10.html)
ME (2) MEP11708A (cg-RX-API-DMAC10.html)
MX (1) MXPA06002639A (cg-RX-API-DMAC10.html)
MY (1) MY136668A (cg-RX-API-DMAC10.html)
NO (2) NO335997B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ545835A (cg-RX-API-DMAC10.html)
PA (1) PA8612401A1 (cg-RX-API-DMAC10.html)
PE (1) PE20050870A1 (cg-RX-API-DMAC10.html)
PL (1) PL1667986T3 (cg-RX-API-DMAC10.html)
PT (1) PT1667986E (cg-RX-API-DMAC10.html)
RS (2) RS54614B1 (cg-RX-API-DMAC10.html)
RU (1) RU2342373C2 (cg-RX-API-DMAC10.html)
SI (1) SI1667986T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN06086A1 (cg-RX-API-DMAC10.html)
TW (1) TWI382022B (cg-RX-API-DMAC10.html)
UA (1) UA87115C2 (cg-RX-API-DMAC10.html)
WO (1) WO2005028462A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200602255B (cg-RX-API-DMAC10.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533330A (ja) * 2006-03-21 2009-09-17 ドクター レディズ ラボラトリーズ リミテッド ドセタキセルの多形体およびプロセス
US7855591B2 (en) * 2006-06-07 2010-12-21 Atmel Corporation Method and system for providing a charge pump very low voltage applications
US7652522B2 (en) * 2006-09-05 2010-01-26 Atmel Corporation High efficiency low cost bi-directional charge pump circuit for very low voltage applications
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
AU2013205442B2 (en) * 2008-01-17 2016-05-12 Aventis Pharma S.A. Crystalline forms of dimethoxy docetaxel and methods for preparing same
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
FR2945211A1 (fr) * 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
CA2708489A1 (en) * 2009-10-29 2011-04-29 Aventis Pharma S.A. Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
CN102770131A (zh) 2009-10-29 2012-11-07 安万特医药股份有限公司 卡巴他赛的新颖抗肿瘤用途
AU2015200149B2 (en) * 2009-10-29 2016-12-01 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN103764637A (zh) * 2011-04-12 2014-04-30 普拉斯化学品有限公司 卡巴他赛的固态形式及其制备方法
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
TWI526437B (zh) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
US8722900B2 (en) 2011-10-31 2014-05-13 Scinopharm Taiwan, Ltd. Process for cabazitaxel, and intermediates thereof
EP2773629B1 (en) 2011-11-01 2018-04-11 Fresenius Kabi Oncology Limited Process for the preparation of an amorphous form of cabazitaxel
DE112012004944T5 (de) 2011-11-28 2014-12-11 Fresenius Kabi Oncology Ltd. Kristalline Formen von Cabazitaxel und deren Herstellungsverfahren
JP6025861B2 (ja) 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
US9403785B2 (en) 2012-01-03 2016-08-02 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
CN104334172A (zh) * 2012-02-10 2015-02-04 安万特医药股份有限公司 卡巴利他索(cabazitaxel)之新颖小儿药用途
EP2822932A2 (en) 2012-03-08 2015-01-14 IVAX International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102675257B (zh) * 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
EP2880021A4 (en) 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd AMORPHIC CABACITAXEL
TWI599373B (zh) 2012-08-15 2017-09-21 永信藥品工業股份有限公司 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之穩定醫藥調配物
CN103664836B (zh) * 2012-09-20 2016-04-20 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
EP2743264A1 (en) 2012-12-13 2014-06-18 INDENA S.p.A. New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103910698B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛丙酮合物及其结晶
CN103910696B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛异丙醚合物及其结晶
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
CN104277014A (zh) * 2013-07-04 2015-01-14 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
WO2015000165A1 (zh) * 2013-07-04 2015-01-08 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
EP2865675A1 (en) * 2013-10-23 2015-04-29 INDENA S.p.A. A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
EP2865674A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
CN103601704B (zh) * 2013-11-22 2015-05-06 石家庄智恒医药科技有限公司 无定形卡巴他赛的制备
US20180311203A1 (en) 2015-01-12 2018-11-01 Emcure Pharmaceuticals Limited Liquid formulation of cabazitaxel
ES2817331T3 (es) 2015-02-17 2021-04-07 Univ Erasmus Med Ct Rotterdam Uso del cabazitaxel en el tratamiento del cáncer de próstata
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
CA3043499A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
CA3073957A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. Pharmaceutical compositions comprising sepiapterin and uses thereof
MX2020012980A (es) 2018-05-30 2021-04-29 Ptc Therapeutics Mp Inc Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.
ES2986920T3 (es) 2018-05-30 2024-11-13 Ptc Therapeutics Mp Inc Administración de sepiapterina sin alimentos para su uso en un método para aumentar la exposición plasmática a sepiapterina
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3797834A1 (en) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032869A1 (fr) * 1996-03-06 1997-09-12 Rhone-Poulenc Rorer S.A. Taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US5889043A (en) * 1995-03-27 1999-03-30 Rhone-Poulenc Rorer S.A. Taxoids, preparation thereof and pharmaceutical Compositions containing same
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
DE4425978C1 (de) * 1994-07-22 1995-11-23 Karlsruhe Forschzent Verfahren zur Herstellung keramischer Mikrostrukturen
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) * 1999-01-07 1999-10-19 508037 (Nb) Inc. Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
CA2373819A1 (en) * 1999-05-17 2000-11-23 Bristol-Myers Squibb Company Novel reaction conditions for the cleavage of silyl ethers in the preparation of paclitaxel (taxol) and paclitaxel analogues
MXPA04005192A (es) * 2001-11-29 2005-02-22 Daiichi Seiyaku Co Cristal de derivado de taxano y metodo para preparar el mismo.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889043A (en) * 1995-03-27 1999-03-30 Rhone-Poulenc Rorer S.A. Taxoids, preparation thereof and pharmaceutical Compositions containing same
WO1997032869A1 (fr) * 1996-03-06 1997-09-12 Rhone-Poulenc Rorer S.A. Taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain

Also Published As

Publication number Publication date
DK1667986T3 (da) 2013-05-06
LU92172I9 (cg-RX-API-DMAC10.html) 2019-01-03
UA87115C2 (ru) 2009-06-25
RU2006113122A (ru) 2006-08-27
KR101123588B1 (ko) 2012-03-22
CN1849311A (zh) 2006-10-18
NZ545835A (en) 2009-10-30
CR8292A (es) 2008-10-15
CY2013016I2 (el) 2018-01-10
CA2539309A1 (fr) 2005-03-31
HK1093340A1 (zh) 2007-03-02
EP1667986A1 (fr) 2006-06-14
MA28045A1 (fr) 2006-07-03
BRPI0414492A8 (pt) 2019-01-15
IL174240A (en) 2010-12-30
ME00054B (me) 2011-02-10
NO20061714L (no) 2006-04-19
PE20050870A1 (es) 2005-11-21
NO335997B1 (no) 2015-04-20
KR20060072147A (ko) 2006-06-27
FR13C0037I1 (fr) 2013-09-08
ES2403149T3 (es) 2013-05-14
RS54614B1 (sr) 2016-08-31
MXPA06002639A (es) 2006-06-05
ES2403149T4 (es) 2013-06-24
US20050065138A1 (en) 2005-03-24
NO2015013I2 (no) 2015-04-22
BE2013C036I2 (cg-RX-API-DMAC10.html) 2023-12-14
PL1667986T3 (pl) 2013-06-28
NO2015013I1 (no) 2015-05-04
PA8612401A1 (es) 2005-08-04
JP5010279B2 (ja) 2012-08-29
IL174240A0 (en) 2006-08-01
AR045667A1 (es) 2005-11-02
CY2013016I1 (el) 2018-01-10
AU2004274212A1 (en) 2005-03-31
MY136668A (en) 2008-11-28
FR2859996A1 (fr) 2005-03-25
ZA200602255B (en) 2007-07-25
FR2859996B1 (fr) 2006-02-03
BRPI0414492A (pt) 2006-11-14
RU2342373C2 (ru) 2008-12-27
SI1667986T1 (sl) 2013-05-31
WO2005028462A1 (fr) 2005-03-31
HRP20130322T1 (en) 2013-07-31
TNSN06086A1 (en) 2007-10-03
HUS1300025I1 (hu) 2016-08-29
RS20060189A (sr) 2008-06-05
TW200524891A (en) 2005-08-01
FR13C0037I2 (fr) 2015-11-20
EP1667986B1 (fr) 2013-01-16
CY1114575T1 (el) 2016-10-05
TWI382022B (zh) 2013-01-11
LU92172I2 (fr) 2013-05-21
CN100429207C (zh) 2008-10-29
US7241907B2 (en) 2007-07-10
PT1667986E (pt) 2013-04-24
MEP11708A (en) 2010-06-10
JP2007505866A (ja) 2007-03-15

Similar Documents

Publication Publication Date Title
AU2004274212B2 (en) Dimethoxy docetaxel acetone solvate et method for the preparation thereof
CN110088118B (zh) 三硫化谷胱甘肽二水合物的晶体及其制造方法
RU2341530C2 (ru) Термостойкий кристаллический гидрохлорид эпирубицина и способ его получения
CN101918385A (zh) 二甲氧基多西紫杉醇的结晶形式及其制备方法
CN101652356A (zh) 稳定的无水晶体多西他赛及其制备方法
JPWO2017086443A1 (ja) ６’−シアリルラクトースナトリウム塩の結晶およびその製造方法
AP750A (en) Method for preparing 4,10-diacetoxy-2a-benzoyloxy-5b, 20-epoxy-1, 7b-dihydroxy-9-oxo-tax-11-en-13a-y) (2r,3s) -3-benzoylamono-2-hydroxy-3-Phenylpropionate trihydrate.
AU2014339222A1 (en) A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
HK1093340B (en) Dimethoxy docetaxel acetone solvate et method for the preparation thereof
KR102476954B1 (ko) 3'-시알릴락토오스나트륨염·n수화물의 결정 및 그 제조 방법
HK1141289A (en) Stable anhydrous crystalline docetaxel and method for the preparation thereof
MXPA97005460A (en) Procedure for the preparation of trihydrate (2r, 3s) -3-benzoylamino-2-hydroxy-3-phenylpropionate de4, 10-diacetoxy-2alfa-benzoiloxi-5beta; 20-epoxy-1, 7beta-dihidroxi-9-oxo-tax -11-en-13alfa-

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: JEVTANA CABAZITAXEL

Filing date: 20111208

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: JEVTANA CABAZITAXEL

Filing date: 20111208

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: JEVTANA CABAZITAXEL

Filing date: 20111208

Extension date: 20261208